KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $6.4 million.

  • Esperion Therapeutics' Net Cash Flow rose 11432.26% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$52.3 million, marking a year-over-year decrease of 27490.97%. This contributed to the annual value of $62.5 million for FY2024, which is 24699.6% up from last year.
  • Esperion Therapeutics' Net Cash Flow amounted to $6.4 million in Q3 2025, which was up 11432.26% from -$28.6 million recorded in Q2 2025.
  • Esperion Therapeutics' Net Cash Flow's 5-year high stood at $144.4 million during Q1 2024, with a 5-year trough of -$87.0 million in Q1 2021.
  • Moreover, its 5-year median value for Net Cash Flow was -$27.4 million (2022), whereas its average is -$11.2 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first crashed by 229919.81% in 2022, then skyrocketed by 61692.99% in 2024.
  • Esperion Therapeutics' Net Cash Flow (Quarter) stood at $105.2 million in 2021, then crashed by 180.43% to -$84.6 million in 2022, then skyrocketed by 61.49% to -$32.6 million in 2023, then soared by 100.14% to $44000.0 in 2024, then soared by 14413.64% to $6.4 million in 2025.
  • Its Net Cash Flow was $6.4 million in Q3 2025, compared to -$28.6 million in Q2 2025 and -$30.1 million in Q1 2025.